Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mesenchymal stem cell substitute product containing degradable biomedical sustained-release material and application thereof

A slow-release material and biomedical technology, applied in the direction of medical preparations containing active ingredients, medical preparations with non-active ingredients, drug combinations, etc., can solve the problem of conditional medium that is difficult to achieve batch-to-batch quality stability and difficulty Stable batch-to-batch quality, difficult to develop drugs and other issues, to achieve the effect of simple storage and transportation, low cost, and clear functional ingredients

Inactive Publication Date: 2018-11-16
TIANJIN AMCELLGENE ENG
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current alternative therapy includes the following methods: 1) The conditioned medium of MSC can play a therapeutic role, but the conditioned medium is difficult to achieve stable quality between batches, making it difficult to develop into a drug. At present, there are some candidate components ( PGE 2 , HGF, TSG-6, etc.), our previous studies have proved that the immune regulation function of UC-MSC is mainly through PGE 2 Realization; 2) MSC exosomes have been proven to have therapeutic effects, but like conditioned medium, it is difficult to achieve stable quality between batches. Clinical application; 3) MSCs survive short in recipients. In normal immune animals, most MSCs die in a short period of time, and only a few parts can be detected by PCR.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mesenchymal stem cell substitute product containing degradable biomedical sustained-release material and application thereof
  • Mesenchymal stem cell substitute product containing degradable biomedical sustained-release material and application thereof
  • Mesenchymal stem cell substitute product containing degradable biomedical sustained-release material and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] [Example 1]: sodium alginate / gelatin / EGF / VEGF / bFGF / PGE 2 Cytotoxicity profile of sustained-release gel (skin damage)

[0050] Combine 0.1mg of sterile sodium alginate and 0.1mg of gelatin into a blended powder, dissolve it in 8.8ml of amino acid injection, swell at room temperature for 24 hours, then add 500ulEGF, 100ulVEGF, 100ulbFGF, 500ulPGE 2 , fully stirred and mixed to prepare a slow-release gel; prepare the extract of the slow-release gel sample according to the above method, after 12h, 24h and 36h of the sample extract and L929 cells were co-cultured, the experimental results showed ( figure 1 ), as the culture time prolongs, there is no significant difference between the sample group and the negative control group (p * 2 Sustained-release gel has good cell compatibility.

Embodiment 2

[0051] [Example 2]: sodium alginate / gelatin / EGF / VEGF / bFGF / PGE 2 Three-dimensional structure diagram of sustained-release gel (skin damage)

[0052] Such as figure 2 Shown, is embodiment 1 sodium alginate / gelatin / EGF / VEGF / bFGF / PGE 2 Three-dimensional structural electron microscope image, it can be seen that microporous structures with different diameters and sizes are formed on the surface of the slow-release gel, and a uniform texture structure appears, which is caused by the accumulation of sodium alginate and gelatin molecules, and sodium alginate / gelatin The structure after physical blending between them is relatively stable. In addition, the microporous structure of the slow-release gel can provide channels for vascularization, accelerate the formation of blood vessels, and facilitate the release of secreted factors, which is beneficial to the repair of skin damage.

Embodiment 3

[0053] [Example 3]: sodium alginate / gelatin / EGF / VEGF / bFGF / PGE 2 Sustained-release gel on the proliferation of human epithelial stem cells (skin damage)

[0054] Human epithelial stem cells in good condition and in the logarithmic growth phase were used in this experiment, and commercially purchased human epithelial stem cells were used in 1×10 4 The cells / well are inoculated in a 96-well plate containing the test sample and negative control, the test sample and negative control are sodium alginate / gelatin / EGF / VEGF / bFGF / PGE respectively 2 Slow-release gel (medium containing 1% serum) and medium containing 1% serum, placed at 37°C, 5% CO 2 The culture was continued for 24 h in the incubator, and the proliferation rate of the cells was detected with Alamar Blue reagent (purchased from Thermo Fisher Scientific). The results show( image 3 ), compared with the negative control group, the sustained-release gel significantly increased the proliferation rate of human epithelial ste...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a mesenchymal stem cell substitute product containing a degradable biomedical sustained-release material and application thereof. The mesenchymal stem cell substitute product comprises the following ingredients (by weight): 1-5% of the degradable biomedical sustained-release material, 0.1-5% of a mesenchymal stem cell secreted factor and the balance an electrolyte injection. The degradable biomedical sustained-release material is a medicinal raw material with plasticity, biocompatibility, histocompatibility and degradation product safety. The sustained-release materialis processed into slow-release gel or sustained-release microspheres wit different particle sizes. By a swelling blending method and / or a high voltage electrostatic method, the prepared ''mesenchymalstem cell paracrine mimetic'' containing the biomedical sustained-release material and the secreted factor has good biocompatibility and slow release performance, has no cytotoxicity, can promote corresponding cell proliferation, has good freeze-drying stability, can be directly stored at low temperature, is convenient to store and transport, helps reduce pollution risk caused by man-made operation, and can be directly used after being unfrozen.

Description

technical field [0001] The invention relates to a mesenchymal stem cell substitute product—a mesenchymal stem cell paracrine mimic, in particular to a mesenchymal stem cell substitute product containing degradable biomedical slow-release materials and its application. Background technique [0002] Mesenchymal stem cells have good clinical application prospects due to their unique biological functions such as immune regulation, promoting angiogenesis, promoting hematopoietic reconstruction and tissue damage repair, such as: skin damage, autoimmune diseases, cardiovascular diseases, Liver disease, nervous system disease, diabetes, limb ischemia, graft-versus-host disease (GvHD) and ophthalmology and other diseases. At present, several mesenchymal stem cell products have been approved for clinical research or new drugs have been launched. However, due to the following characteristics of mesenchymal stem cells, which affect their large-scale preparation and application: 1) MSCs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A61K31/5575A61K9/06A61K47/10A61K47/34A61K47/36A61K47/42A61P1/16A61P9/00A61P9/10A61P17/02A61P19/02A61P19/04A61P19/08A61P29/00
CPCA61K9/06A61K31/5575A61K38/18A61K38/1808A61K38/1825A61K38/1841A61K38/1866A61K47/10A61K47/34A61K47/36A61K47/42A61P1/16A61P9/00A61P9/10A61P17/02A61P19/02A61P19/04A61P19/08A61P29/00A61K2300/00
Inventor 韩之波喻昊李宗金赵钦军韩忠朝
Owner TIANJIN AMCELLGENE ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com